EBC-129 is a first-in-class antibody drug conjugate (ADC) targeting a novel, tumor-specific N256-glycosylated epitope on CEACAM5 and CEACAM6. The updated findings showed promising efficacy data ...

This binding is largely independent of the substrate itself, allowing tethering of the conjugate while the substrate moiety is unfolded and degraded. De-ubiquitinating enzymes can recycle the ...

a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. SIM0505 is currently in Phase 1 clinical testing in China; NextCure expects to begin ...

SAN FRANCISCO, June 02, 2025--(BUSINESS WIRE)--Kivu Bioscience, a biotech company developing next-generation antibody-drug conjugates, announced today a manufacturing partnership with Sterling ...

Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activation of immune system through multiple mechanisms India represents a ...

a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. SIM0505 is currently in Phase 1 clinical testing in China; NextCure expects to ...

EBC-129 is the first made-in-Singapore antibody-drug conjugate (ADC) to enter clinical development. It selectively targets a tumour-specific N-glycosylated epitope on both CEACAM5 and CEACAM6. The ...

(MENAFN- GlobeNewsWire - Nasdaq) Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activation of immune system through ...

- Agreement grants Astellas exclusive worldwide rights (excluding China's mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW27011 - - XNW27011 has demonstrated ...

DB-1310 is an antibody-drug conjugate (ADC), a type of therapy designed to deliver a powerful chemotherapy drug directly to cancer cells while minimizing damage to healthy tissue. The drug ...